Cold activation of complement and kinin. 1979

M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda

Differences between serum and plasma complement, which now is called as the cold activation of complement, was investigated in relation with the phenomenon reported as the cold promoted activation of factor VII, to which kallikrein and Hageman factor are known to participate. Despite the presence of several similarities in these two phenomena, it is concluded that the cold activation of complement is not related to the coagulation nor the kinin system. Evidence that tranexamic acid, a potent antiplasmin compound, provided an inhibitory effect on the cold activation of complement, suggested that the phenomenon could not be explained by a single mechanism, and plasmin might be involved in the phenomenon in a limited case.

UI MeSH Term Description Entries
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007705 Kinins A generic term used to describe a group of polypeptides with related chemical structures and pharmacological properties that are widely distributed in nature. These peptides are AUTACOIDS that act locally to produce pain, vasodilatation, increased vascular permeability, and the synthesis of prostaglandins. Thus, they comprise a subset of the large number of mediators that contribute to the inflammatory response. (From Goodman and Gilman's The Pharmacologic Basis of Therapeutics, 8th ed, p588) Kinin
D009994 Osmolar Concentration The concentration of osmotically active particles in solution expressed in terms of osmoles of solute per liter of solution. Osmolality is expressed in terms of osmoles of solute per kilogram of solvent. Ionic Strength,Osmolality,Osmolarity,Concentration, Osmolar,Concentrations, Osmolar,Ionic Strengths,Osmolalities,Osmolar Concentrations,Osmolarities,Strength, Ionic,Strengths, Ionic
D003080 Cold Temperature An absence of warmth or heat or a temperature notably below an accustomed norm. Cold,Cold Temperatures,Temperature, Cold,Temperatures, Cold
D003165 Complement System Proteins Serum glycoproteins participating in the host defense mechanism of COMPLEMENT ACTIVATION that creates the COMPLEMENT MEMBRANE ATTACK COMPLEX. Included are glycoproteins in the various pathways of complement activation (CLASSICAL COMPLEMENT PATHWAY; ALTERNATIVE COMPLEMENT PATHWAY; and LECTIN COMPLEMENT PATHWAY). Complement Proteins,Complement,Complement Protein,Hemolytic Complement,Complement, Hemolytic,Protein, Complement,Proteins, Complement,Proteins, Complement System
D004492 Edetic Acid A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive. EDTA,Edathamil,Edetates,Ethylenediaminetetraacetic Acid,Tetracemate,Calcium Disodium Edetate,Calcium Disodium Versenate,Calcium Tetacine,Chelaton 3,Chromium EDTA,Copper EDTA,Coprin,Dicobalt EDTA,Disodium Calcitetracemate,Disodium EDTA,Disodium Ethylene Dinitrilotetraacetate,Distannous EDTA,Edetate Disodium Calcium,Edetic Acid, Calcium Salt,Edetic Acid, Calcium, Sodium Salt,Edetic Acid, Chromium Salt,Edetic Acid, Dipotassium Salt,Edetic Acid, Disodium Salt,Edetic Acid, Disodium Salt, Dihydrate,Edetic Acid, Disodium, Magnesium Salt,Edetic Acid, Disodium, Monopotassium Salt,Edetic Acid, Magnesium Salt,Edetic Acid, Monopotassium Salt,Edetic Acid, Monosodium Salt,Edetic Acid, Potassium Salt,Edetic Acid, Sodium Salt,Ethylene Dinitrilotetraacetate,Ethylenedinitrilotetraacetic Acid,Gallium EDTA,Magnesium Disodium EDTA,N,N'-1,2-Ethanediylbis(N-(carboxymethyl)glycine),Potassium EDTA,Stannous EDTA,Versenate,Versene,Acid, Edetic,Acid, Ethylenediaminetetraacetic,Acid, Ethylenedinitrilotetraacetic,Calcitetracemate, Disodium,Dinitrilotetraacetate, Disodium Ethylene,Dinitrilotetraacetate, Ethylene,Disodium Versenate, Calcium,EDTA, Chromium,EDTA, Copper,EDTA, Dicobalt,EDTA, Disodium,EDTA, Distannous,EDTA, Gallium,EDTA, Magnesium Disodium,EDTA, Potassium,EDTA, Stannous,Edetate, Calcium Disodium,Ethylene Dinitrilotetraacetate, Disodium,Tetacine, Calcium,Versenate, Calcium Disodium
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005167 Factor VII Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor VIIa in the extrinsic pathway of blood coagulation. The activated form then catalyzes the activation of factor X to factor Xa. Coagulation Factor VII,Proconvertin,Stable Factor,Blood Coagulation Factor VII,Factor 7,Factor Seven,Factor VII, Coagulation
D005174 Factor XII Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III. Coagulation Factor XII,Hageman Factor,Factor 12,Factor Twelve

Related Publications

M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
January 1973, International archives of allergy and applied immunology,
M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
January 1992, Vox sanguinis,
M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
December 1994, Infusionstherapie und Transfusionsmedizin,
M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
January 2004, Clinical chemistry and laboratory medicine,
M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
September 1992, Journal of clinical immunology,
M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
January 1981, Przeglad lekarski,
M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
May 1992, Internal medicine (Tokyo, Japan),
M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
September 1984, Scandinavian journal of gastroenterology,
M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
October 1969, Deutsche medizinische Wochenschrift (1946),
M Kondo, and S Takemura, and T Yoshikawa, and H Kato, and N Yokoe, and M Ikezaki, and K Hosokawa, and M Masuda
September 2019, EBioMedicine,
Copied contents to your clipboard!